Torus Biosystems develops molecular diagnostic tests for infectious diseases using advanced nucleic acid amplification techniques. Their technology provides rapid and accurate detection of pathogens, enabling timely clinical decision-making and improving patient outcomes.
Funding
$25M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current molecular diagnostic tests for infectious diseases often require complex laboratory procedures and specialized equipment, leading to delays in obtaining results and hindering timely clinical decision-making. This can negatively impact patient outcomes, particularly in settings with limited resources or urgent clinical needs.
Solution
Torus Biosystems is developing advanced molecular diagnostic tests for infectious diseases that leverage nucleic acid amplification techniques to enable rapid and accurate pathogen detection. Their technology aims to simplify the testing process, potentially reducing the time required to obtain results and facilitating faster clinical interventions. By providing timely and reliable diagnostic information, Torus Biosystems seeks to improve patient outcomes and support effective disease management.
Target Audience
The primary target audience includes healthcare providers, clinical laboratories, and hospitals seeking rapid and accurate diagnostic solutions for infectious diseases.
Features
- Advanced nucleic acid amplification techniques for pathogen detection
- Rapid turnaround time for test results
- Simplified testing process for ease of use
- Accurate and reliable diagnostic information